MAY 15 (Reuters) – ZURICH Sandoz is Novartis’s generics service, which it plans to spin off to investors later this year, and on Monday, the company called the wanted new board members.
The Basel company approved Gilbert Ghostine’s nominations for the 10 members of the Sandoz board, who will begin pre-operational work in June.
Francois-Xavier Roger, the current Chief Financial Officer of Nestle NESN, is one of the new members.SUrs Riedener, a former CEO of dairy conglomerate Emmi EMMN.S, and Shamiram Feinglass, a former Chief Medical Officer for Life Sciences at medical innovation firm Danaher DHR.N, have joined forces to form a new company.
Ex-Novartis executive Karen Huebscher, Eli Lilly LLY.N employee Aarti Shah, and Deutsche Lufthansa LHAG.DE’s Chief Financial Officer Remco Steenburgen are among the other candidates for board membership.
Maria Varsellona, CLO of Unilever ULVR.L, and Yannis Skoufalos, formerly of Procter & Gamble PG.N, are the two newly elected members of the committee.
After receiving agreement from the Novartis Board of Directors and investors, “the Sandoz Board of Directors will begin preparatory work from June onwards and will work following the prepared spin-off of Sandoz in the 2nd half of 2023,” Novartis said on Monday.